NCT07115927View on ClinicalTrials.gov

pReOperative Dostarlimab and Novel Therapies in EndOmetrial Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

April 30, 2030

Study Completion Date

January 31, 2031

Conditions
Endometrial Cancer
Interventions
DRUG

Dostarlimab

Arm 1: Patients in the initial cohort will be treated with two doses of dostarlimab prior to surgery, receiving dostarlimab 500mg IV on day 1 and day 22.

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University College, London

OTHER

NCT07115927 - pReOperative Dostarlimab and Novel Therapies in EndOmetrial Cancer | Biotech Hunter | Biotech Hunter